skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same

Abstract

Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.

Inventors:
 [1];  [2]
  1. Benicia, CA
  2. Berkeley, CA
Issue Date:
Research Org.:
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
909426
Patent Number(s):
7223726
Application Number:
10/342,965
Assignee:
The Regents of the University of California (Oakland, CA)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
DOE Contract Number:  
AC03-76SF00098
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Oda, Michael N, and Forte, Trudy M. Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same. United States: N. p., 2007. Web.
Oda, Michael N, & Forte, Trudy M. Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same. United States.
Oda, Michael N, and Forte, Trudy M. Tue . "Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same". United States. https://www.osti.gov/servlets/purl/909426.
@article{osti_909426,
title = {Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same},
author = {Oda, Michael N and Forte, Trudy M},
abstractNote = {Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2007},
month = {5}
}

Patent:

Save / Share:

Works referenced in this record:

Hydrolysis of platelet-activating factor by human serum paraoxonase
journal, February 2001


Characterization of human apolipoprotein A-I expressed in Escherichia coli
journal, January 1997


Dietary Fat Modulates Serum Paraoxonase 1 Activity in Rats
journal, October 2000


Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein
journal, December 1997


Human Serum Paraoxonase
journal, September 1998


Serum Paraoxonase Activity and the Extent of Lipid Peroxidation Are not Affected by Increased Levels of Human Apolipoprotein A-I: Studies in Transgenic Mice
journal, January 2002


High-density lipoprotein composition and paraoxonase activity in Type I diabetes
journal, November 2001


Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
journal, April 1998


Serum Paraoxonase After Myocardial Infarction
journal, February 1999


Recombinant apolipoproteins for the treatment of vascular diseases
journal, January 1999


Paraoxonase 1 Overexpression in Mice and Its Effect on High-Density Lipoproteins
journal, January 2002


Optimized bacterial expression of human apolipoprotein A-I
journal, January 2003


Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activity
journal, February 2001


Subjects With ApoA-I(Lys 107 →0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)
journal, May 1997


Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
journal, July 1998